Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab (Enyitan) for adolescent chronic spontaneous urticaria – Phase IV China
CTR20260466Phase 4Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of omalizumab in chronic idiopathic urticaria (CIU), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Feb 2026; status: active.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20260466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260466.